Benjamin F. Edwards & Company, Inc. Rubius Therapeutics, Inc. Call Options Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RUBY
# of Institutions
2Shares Held
325Call Options Held
0Put Options Held
0About Rubius Therapeutics, Inc.
- Ticker RUBY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,357,000
- Description
- Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...